Viking Therapeutics Schedules Q4 2025 Earnings Release and Conference Call
Event summary
- Viking Therapeutics will release Q4 and full-year 2025 financial results on February 11, 2026.
- Conference call scheduled for 4:30 p.m. Eastern Time on February 11, 2026.
- Company is advancing multiple clinical programs, including VK2735 for obesity and VK2809 for NASH.
- VK0214 Phase 1b trial showed significant reductions in VLCFAs for X-ALD treatment.
The big picture
Viking Therapeutics is navigating a competitive landscape in metabolic and endocrine disorder treatments, with its pipeline positioning it against established players and emerging biotech firms. The company's focus on novel therapies like VK2735 and VK2809 could disrupt existing treatment paradigms if clinical and regulatory milestones are met. The upcoming earnings release will provide insights into the financial health and operational efficiency of the company as it scales its clinical programs.
What we're watching
- Clinical Progress
- The pace at which Viking Therapeutics advances its Phase 3 obesity trials (VANQUISH-1 and VANQUISH-2) will be critical for its strategic positioning.
- Regulatory Dynamics
- Whether VK2809's Phase 2b success in NASH translates into regulatory approvals and market adoption.
- Financial Performance
- How Viking Therapeutics' financial results reflect its R&D investments and potential path to profitability.
Related topics